NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

GPCR

Structure Therapeutics Inc ADR

Jul 01 • 03:09PM ET

20.92

Dollar change +0.18
Percentage change 0.87	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN BMY GILD BIIB AMGN MRNA NBIX NKTR INCY

| Held by: IBB OZEM FDG LRNZ SBIO HRTS ONEQ GXC FMED BBC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.58	Insider Own	4.94%	Shs Outstand	57.54M	Perf Week	-6.52%
Market Cap	1.20B	Forward P/E	-	EPS next Y	-1.49	Insider Trans	0.00%	Shs Float	54.69M	Perf Month	-3.86%
Enterprise Value	374.44M	PEG	-	EPS next Q	-0.28	Inst Own	93.69%	Short Float	15.13%	Perf Quarter	20.85%
Income	-143.51M	P/S	-	EPS this Y	-8.98%	Inst Trans	-8.29%	Short Ratio	8.50	Perf Half Y	-29.18%
Sales	0.00M	P/B	1.46	EPS next Y	-75.50%	ROA	-21.68%	Short Interest	8.27M	Perf YTD	-22.86%
Book/sh	14.33	P/C	1.44	EPS next 5Y	-29.13%	ROE	-22.88%	52W High	47.48 -55.94%	Perf Year	-46.55%
Cash/sh	14.54	P/FCF	-	EPS past 3/5Y	-24.81% -51.75%	ROIC	-17.30%	52W Low	13.22 58.25%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.92% 6.14%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-11.34%	Oper. Margin	-	ATR (14)	1.35	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	23.29	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	42.27	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	23.29	EPS Q/Q	-46.51%	SMA20	-2.81%	Beta	-1.97	Target Price	80.50
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	-10.38%	Rel Volume	0.35	Prev Close	20.74
Employees	163	LT Debt/Eq	0.01	Earnings	May 08 AMC	SMA200	-26.06%	Avg Volume	973.64K	Price	20.92
IPO	Feb 03, 2023	Option/Short	Yes / Yes	EPS/Sales Surpr.	-11.93% -	Trades		Volume	297,256	Change	0.87%

Date	Action	Analyst	Rating Change	Price Target Change
May-02-25	Initiated	Citigroup	Buy	$60
Feb-28-25	Initiated	William Blair	Outperform
Jan-08-25	Initiated	Stifel	Buy	$50
Dec-04-24	Initiated	H.C. Wainwright	Buy	$80
Sep-23-24	Initiated	Morgan Stanley	Overweight	$118
May-21-24	Initiated	JP Morgan	Overweight	$65
Apr-09-24	Initiated	Cantor Fitzgerald	Overweight	$65
Oct-19-23	Initiated	JMP Securities	Mkt Outperform	$90
Jul-27-23	Initiated	Piper Sandler	Overweight	$58
May-25-23	Resumed	Jefferies	Buy	$34 → $41
Feb-28-23	Initiated	SVB Securities	Outperform	$33
Feb-28-23	Initiated	Jefferies	Buy	$34
Feb-28-23	Initiated	Guggenheim	Buy	$50
Feb-28-23	Initiated	BMO Capital Markets	Outperform	$40

Show Previous Ratings

Jun-24-25 05:42PM	Jefferies Reiterates a Buy Rating on Structure Therapeutics (GPCR) With a $79 PT (Insider Monkey)
Jun-20-25 07:30PM	Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671 (GlobeNewswire)
May-29-25 04:05PM	Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences (GlobeNewswire)
May-08-25 04:05PM	Structure Therapeutics Reports First Quarter 2025 Financial Results and Recent Highlights (GlobeNewswire)
Apr-25-25 04:31PM	Is Structure Therapeutics Inc. (NASDAQ:GPCR) the Most Promising Small-Cap Stock According to Analysts? (Insider Monkey)
08:37AM	Loading…
Apr-21-25 08:37AM	LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study (Zacks) +6.16%
Apr-18-25 11:25AM	Eli Lilly jumps as results from weight-loss pill study rival competitors (TipRanks)
10:26AM	JPMorgan says Lilly data highly favorable for Structure Therapeutics (TipRanks)
Apr-15-25 10:35AM	Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill (TipRanks)
10:00AM	NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback (Zacks)
Apr-14-25 11:12AM	Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today (Motley Fool) +19.18%
Mar-24-25 07:21PM	Structure Therapeutics CEO on latest GLP-1 developments (CNBC TV)
Mar-20-25 09:28AM	Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate (SeekingAlpha)
Mar-03-25 04:20PM	AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion. (Investor's Business Daily) -5.94%
Feb-27-25 04:05PM	Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights (GlobeNewswire) +14.79%
07:56AM	Loading…
Feb-14-25 07:56AM	Why Structure Therapeutics Stock Was Stumbling This Week (Motley Fool)
Jan-30-25 08:30AM	Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences (GlobeNewswire)
Dec-18-24 10:25AM	Merck Licenses a Weight-Loss Pill. Its Bad News for Obesity Biotechs. (Barrons.com) -11.37%
Dec-17-24 04:01PM	Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity (GlobeNewswire)
Dec-16-24 01:33PM	Is Structure Therapeutics Inc. (GPCR) the Best Weight Loss Stock to Buy Now According to Hedge Funds? (Insider Monkey)
Dec-08-24 06:05AM	Jefferies Predicts Up to ~1000% Surge for These 2 Strong Buy Stocks (TipRanks)
Nov-27-24 10:15AM	Why Is Structure Therapeutics Inc. (GPCR) Among the Best Up and Coming Stocks to Buy According to Analysts? (Insider Monkey)
Nov-22-24 07:45AM	Structure Therapeutics Inc. (GPCR): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts (Insider Monkey) +11.00%
Nov-15-24 08:30AM	Structure Therapeutics to Participate in the Jefferies London Healthcare Conference (GlobeNewswire) -9.34%
Nov-13-24 04:05PM	Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire)
04:01PM	Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity (GlobeNewswire)
Oct-31-24 08:30AM	Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek 2024 (GlobeNewswire) +8.69%
Oct-24-24 07:58PM	GPCR drugmaker Septerna amasses $288M in IPO (BioPharma Dive)
Oct-16-24 08:45AM	Structure Therapeutics (GPCR): Innovating Oral Therapies for Obesity and Diabetes (Insider Monkey) +7.41%
Oct-09-24 09:55AM	Does Structure Therapeutics Inc. Sponsored ADR (GPCR) Have the Potential to Rally 115.8% as Wall Street Analysts Expect? (Zacks)
08:00AM	Loading…
Oct-04-24 08:00AM	As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer (Investor's Business Daily)
Sep-29-24 02:05AM	Is Structure Therapeutics Inc. (GPCR) the Best Young Stock To Buy Now? (Insider Monkey)
Sep-20-24 01:17PM	High-Flying Novo Nordisk Dips On Disappointing Data for Weight-Loss Pill (The Wall Street Journal) +8.18%
Sep-17-24 04:05PM	Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer (GlobeNewswire)
Sep-05-24 01:07AM	Structure Therapeutics Inc. (GPCR): Among the Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Sep-02-24 06:05PM	10 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-27-24 04:05PM	Structure Therapeutics Appoints Angus C. Russell to Board of Directors (GlobeNewswire)
Aug-26-24 04:05PM	Structure Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Aug-13-24 02:00PM	3 Promising Biotech Stocks for the Long-Term: August 2024 (InvestorPlace)
Aug-12-24 04:08PM	Dont Forget This Start-Ups Weight-Loss Pill, Analyst Says (Barrons.com)
Aug-08-24 08:18PM	Why Are Hedge Funds Bullish on Structure Therapeutics Inc. (GPCR) Now? (Insider Monkey)
04:05PM	Structure Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire)
Jul-30-24 03:07PM	3 Biotech Stocks That Could Make Your Summer Unforgettable (InvestorPlace) -8.75%
Jul-24-24 08:55AM	What's in Store for Structure Therapeutics (GPCR) in Q2 Earnings? (Zacks)
Jul-17-24 10:47AM	Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics? (Benzinga) -14.15%
Jul-12-24 06:08AM	The 3 Most Undervalued Biotech Stocks to Buy in July 2024 (InvestorPlace)
Jun-28-24 10:09AM	The 3 Smartest Biotech Stocks to Buy With $5K Right Now (InvestorPlace)
Jun-17-24 09:53AM	Could Structure Therapeutics Become the Next Novo Nordisk? (Motley Fool)
Jun-11-24 07:31PM	Structure Therapeutics CEO on GLP drugs (CNBC TV) -5.42%
09:59AM	Structure Therapeutics (GPCR) Rallying on Obesity Drug Data (Zacks)
04:57AM	Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy? (Motley Fool)
Jun-09-24 07:30AM	Structure Therapeutics' Stock Is Soaring on the Promise of Its Wegovy Competitor, but Is It a Buy? (Motley Fool)
Jun-07-24 04:05PM	Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares (GlobeNewswire)
05:00AM	Ozempic competitors, psychedelic stocks, and Moderna after COVID: Pharma news roundup (Quartz)
Jun-05-24 07:53PM	Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering (GlobeNewswire)
Jun-04-24 11:59AM	Qiming's Nisa Leung Made the 2024 Forbes Midas List (PR Newswire)
06:00AM	The 3 Most Undervalued Biotech Stocks to Buy in June 2024 (InvestorPlace)
02:03AM	Heard on the Street Monday Recap: Catnip (The Wall Street Journal)
Jun-03-24 06:55PM	Structure Therapeutics is a 'no-brainer takeout' target, says Mizuho's Jared Holz (CNBC TV) +54.21%
04:09PM	Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants (GlobeNewswire)
03:30PM	Structure Therapeutics (GPCR) Stock Soars 60% on Weight Loss Drug Success (InvestorPlace)
01:42PM	Structure Therapeutics Stock Skyrockets To Six-Month High On Compelling Weight-Loss Drug Results (Investor's Business Daily)
01:17PM	The race for a weight loss pill heats up as a Novo Nordisk competitor releases new trial results (Quartz)
12:30PM	Heard on the Street: Wall Street Is Cheering a New Obesity Pill Candidate. Here's Why. (The Wall Street Journal)
11:30AM	Structure Therapeutics Stock Soars on Obesity Pill Data (The Wall Street Journal)
08:20AM	Structure pill leads to competitive weight loss in obesity study (BioPharma Dive)
07:30AM	Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290 (GlobeNewswire)
Jun-02-24 09:07AM	J.P. Morgan Predicts up to 210% Gains for These 2 Strong Buy Stocks (TipRanks)
May-31-24 06:00AM	Unearthing Unknown Stocks: 3 Picks That Could Be the Next Big Thing (InvestorPlace)
May-21-24 07:44AM	JPMorgan Starts Structure Therapeutics With Overweight Rating (MT Newswires)
May-09-24 10:56PM	GPCR Stock Earnings: Structure Therapeutics Beats EPS for Q1 2024 (InvestorPlace) -7.32%
04:05PM	Structure Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire)
10:34AM	7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025 (InvestorPlace)
Apr-24-24 06:33AM	3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains (InvestorPlace)
Mar-30-24 09:37AM	7 Small-Cap Stocks that Wall Street Loves for Good Reason (InvestorPlace)
Mar-15-24 10:53AM	GPCR Stock Earnings: Structure Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
Mar-08-24 04:05PM	Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference (GlobeNewswire)
08:30AM	Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights (GlobeNewswire)
Jan-22-24 05:24AM	Here's Why Structure Therapeutics (GPCR) Fell in Q4 (Insider Monkey)
Dec-25-23 07:45AM	Structure Therapeutics Stock Just Crashed. Here's Why It Could Be Worth Buying Now (Motley Fool)
Dec-22-23 04:21PM	7 Small-Cap Stocks That Wall Street Loves for Good Reason (InvestorPlace) +7.85%
Dec-18-23 04:06PM	Structure Plummets 43% After Trailing Lilly In Obesity Treatment (Investor's Business Daily) -42.82% +10.05%
01:03PM	Another Drugmaker Hits Rocks Seeking a Weight-Loss Pill (The Wall Street Journal)
11:29AM	New Shakeup Hits Obesity Pills. Structure Rolls Out Disappointing Data. (Barrons.com)
09:22AM	Structure Stock Takes A Brutal Beating After Obesity Drug Trails Lilly's Leader (Investor's Business Daily)
07:30AM	Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study (GlobeNewswire)
07:30AM	Structure Therapeutic obesity pill shows promise in mid-stage trial (Reuters)
06:23AM	Structure shares sink as obesity pill misses expectations in small study (BioPharma Dive)
Dec-11-23 12:26PM	3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023 (InvestorPlace)
Nov-29-23 02:28PM	If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 Names (InvestorPlace)
02:30AM	11 Best Young Stocks to Buy and Hold For 20 Years (Insider Monkey)
Nov-27-23 09:50AM	11 Best Upside Stocks To Buy Right Now (Insider Monkey)
Nov-26-23 04:44PM	2 Biotech Stocks That Could Soar in December (Motley Fool)
Nov-14-23 04:10PM	Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire) -9.83%
Nov-03-23 05:20AM	Should You Still Buy the Nasdaq's Best-Performing October Stocks? (Motley Fool)
Oct-19-23 08:45AM	Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders (PR Newswire)
Oct-06-23 08:45AM	Structure Therapeutics (GPCR) Stock Up 9% This Week: Here's Why (Zacks)
Oct-02-23 03:48PM	Why Shares of Structure Therapeutics Are Up Monday (Motley Fool) +12.26%
Sep-29-23 04:04PM	Structure Soars 35% As Newcomer Takes On Behemoths Lilly, Novo In Obesity Treatment (Investor's Business Daily) +34.56%
12:50PM	Why Shares of Structure Therapeutics Are Soaring on Friday (Motley Fool)

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in February 2019 and is headquartered in South San Francisco, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GPCR

Structure Therapeutics Inc ADR

Upgrade your FINVIZ experience